File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Functional categories of TP53 mutation in colorectal cancer: Results of an International Collaborative Study

TitleFunctional categories of TP53 mutation in colorectal cancer: Results of an International Collaborative Study
Authors
KeywordsChemotherapy
Colorectal cancer
Mutation
Prognosis
TP53
Transactivational ability
Issue Date2006
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2006, v. 17 n. 5, p. 842-847 How to Cite?
Abstract
Background: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (≤20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. Materials and methods: TP53 mutations within a large, international database of CRC (n = 3583) were classified according to functional status for transactivation. Results: Inactive TP53 mutations were found in 29% of all CRCs and were more frequent in rectal (32%) than proximal colon (22%) tumours (P < 0.001). Higher frequencies of inactive TP53 mutations were also seen in advanced stage tumours (P = 0.0003) and in tumours with the poor prognostic features of vascular (P = 0.006) and lymphatic invasion (P = 0.002). Inactive TP53 mutations were associated with significantly worse outcome only in patients with Dukes' stage D tumours (RR = 1.71, 95%CI 1.25-2.33, P < 0.001). Patients with Dukes' C stage tumours appeared to gain a survival benefit from 5-fluorouracil-based chemotherapy regardless of TP53 functional status for transactivation ability. Conclusions: Mutations that inactivate the transactivational ability of TP53 are more frequent in advanced CRC and are associated with worse prognosis in this stage of disease. © 2006 Oxford University Press.
Persistent Identifierhttp://hdl.handle.net/10722/88775
ISSN
2013 Impact Factor: 6.578
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorIacopetta, Ben_HK
dc.contributor.authorRusso, Aen_HK
dc.contributor.authorBazan, Ven_HK
dc.contributor.authorDardanoni, Gen_HK
dc.contributor.authorGebbia, Nen_HK
dc.contributor.authorSoussi, Ten_HK
dc.contributor.authorKerr, Den_HK
dc.contributor.authorElsaleh, Hen_HK
dc.contributor.authorSoong, Ren_HK
dc.contributor.authorKandioler, Den_HK
dc.contributor.authorJanschek, Een_HK
dc.contributor.authorKappel, Sen_HK
dc.contributor.authorLung, Men_HK
dc.contributor.authorLeung, CSSen_HK
dc.contributor.authorKo, JMen_HK
dc.contributor.authorYuen, Sen_HK
dc.contributor.authorHo, Jen_HK
dc.contributor.authorLeung, SYen_HK
dc.contributor.authorCrapez, Een_HK
dc.contributor.authorDuffour, Jen_HK
dc.contributor.authorYchou, Men_HK
dc.contributor.authorLeahy, DTen_HK
dc.contributor.authorO'Donoghue, DPen_HK
dc.contributor.authorAgnese, Ven_HK
dc.contributor.authorCascio, Sen_HK
dc.contributor.authorDi Fede, Gen_HK
dc.contributor.authorChiecoBianchi, Len_HK
dc.contributor.authorBertorelle, Ren_HK
dc.contributor.authorBelluco, Cen_HK
dc.contributor.authorGiaretti, Wen_HK
dc.contributor.authorCastagnola, Pen_HK
dc.contributor.authorRicevuto, Een_HK
dc.contributor.authorFicorella, Cen_HK
dc.contributor.authorBosari, Sen_HK
dc.contributor.authorArizzi, CDen_HK
dc.contributor.authorMiyaki, Men_HK
dc.contributor.authorOnda, Men_HK
dc.contributor.authorKampman, Een_HK
dc.contributor.authorDiergaarde, Ben_HK
dc.contributor.authorRoyds, Jen_HK
dc.contributor.authorLothe, RAen_HK
dc.contributor.authorDiep, CBen_HK
dc.contributor.authorMeling, GIen_HK
dc.contributor.authorOstrowski, Jen_HK
dc.contributor.authorTrzeciak, Len_HK
dc.contributor.authorGuzińskaUstymowicz, Ken_HK
dc.contributor.authorZalewski, Ben_HK
dc.contributor.authorCapellá, GMen_HK
dc.contributor.authorMoreno, Ven_HK
dc.contributor.authorPeinado, MAen_HK
dc.contributor.authorLönnroth, Cen_HK
dc.contributor.authorLundholm, Ken_HK
dc.contributor.authorSun, XFen_HK
dc.contributor.authorJansson, Aen_HK
dc.contributor.authorBouzourene, Hen_HK
dc.contributor.authorHsieh, LLen_HK
dc.contributor.authorTang, Ren_HK
dc.contributor.authorSmith, DRen_HK
dc.contributor.authorAllenMersh, TGen_HK
dc.contributor.authorKhan, ZAJen_HK
dc.contributor.authorShorthouse, AJen_HK
dc.contributor.authorSilverman, MLen_HK
dc.contributor.authorKato, Sen_HK
dc.contributor.authorIshioka, Cen_HK
dc.date.accessioned2010-09-06T09:47:50Z-
dc.date.available2010-09-06T09:47:50Z-
dc.date.issued2006en_HK
dc.identifier.citationAnnals Of Oncology, 2006, v. 17 n. 5, p. 842-847en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88775-
dc.description.abstractBackground: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (≤20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. Materials and methods: TP53 mutations within a large, international database of CRC (n = 3583) were classified according to functional status for transactivation. Results: Inactive TP53 mutations were found in 29% of all CRCs and were more frequent in rectal (32%) than proximal colon (22%) tumours (P < 0.001). Higher frequencies of inactive TP53 mutations were also seen in advanced stage tumours (P = 0.0003) and in tumours with the poor prognostic features of vascular (P = 0.006) and lymphatic invasion (P = 0.002). Inactive TP53 mutations were associated with significantly worse outcome only in patients with Dukes' stage D tumours (RR = 1.71, 95%CI 1.25-2.33, P < 0.001). Patients with Dukes' C stage tumours appeared to gain a survival benefit from 5-fluorouracil-based chemotherapy regardless of TP53 functional status for transactivation ability. Conclusions: Mutations that inactivate the transactivational ability of TP53 are more frequent in advanced CRC and are associated with worse prognosis in this stage of disease. © 2006 Oxford University Press.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.rightsAnnals of Oncology. Copyright © Oxford University Press.en_HK
dc.subjectChemotherapyen_HK
dc.subjectColorectal canceren_HK
dc.subjectMutationen_HK
dc.subjectPrognosisen_HK
dc.subjectTP53en_HK
dc.subjectTransactivational abilityen_HK
dc.subject.meshAdenocarcinoma - drug therapy - genetics - pathologyen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshColorectal Neoplasms - drug therapy - genetics - pathologyen_HK
dc.subject.meshDNA Mutational Analysisen_HK
dc.subject.meshExonsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInternational Agenciesen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMutationen_HK
dc.subject.meshNeoplasm Invasiveness - genetics - pathologyen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTumor Suppressor Protein p53 - geneticsen_HK
dc.titleFunctional categories of TP53 mutation in colorectal cancer: Results of an International Collaborative Studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=17&issue=5&spage=842&epage=7&date=2006&atitle=Functional+categories+of+TP53+mutation+in+colorectal+cancer:+results+of+an+International+Collaborative+Studyen_HK
dc.identifier.emailLung, M:mlilung@hku.hken_HK
dc.identifier.emailLeung, SY:suetyi@hkucc.hku.hken_HK
dc.identifier.authorityLung, M=rp00300en_HK
dc.identifier.authorityLeung, SY=rp00359en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdl035en_HK
dc.identifier.pmid16524972en_HK
dc.identifier.scopuseid_2-s2.0-33646183787en_HK
dc.identifier.hkuros116117en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646183787&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue5en_HK
dc.identifier.spage842en_HK
dc.identifier.epage847en_HK
dc.identifier.isiWOS:000237174200017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridIacopetta, B=7005494393en_HK
dc.identifier.scopusauthoridRusso, A=7402518728en_HK
dc.identifier.scopusauthoridBazan, V=6701853118en_HK
dc.identifier.scopusauthoridDardanoni, G=7003849221en_HK
dc.identifier.scopusauthoridGebbia, N=35474178500en_HK
dc.identifier.scopusauthoridSoussi, T=7103147773en_HK
dc.identifier.scopusauthoridKerr, D=25931607500en_HK
dc.identifier.scopusauthoridElsaleh, H=7003779103en_HK
dc.identifier.scopusauthoridSoong, R=9738714100en_HK
dc.identifier.scopusauthoridKandioler, D=6603986012en_HK
dc.identifier.scopusauthoridJanschek, E=6602957128en_HK
dc.identifier.scopusauthoridKappel, S=6602727864en_HK
dc.identifier.scopusauthoridLung, M=7006411788en_HK
dc.identifier.scopusauthoridLeung, CSS=7402612613en_HK
dc.identifier.scopusauthoridKo, JM=35725559400en_HK
dc.identifier.scopusauthoridYuen, S=7103160927en_HK
dc.identifier.scopusauthoridHo, J=25925854200en_HK
dc.identifier.scopusauthoridLeung, SY=7202044886en_HK
dc.identifier.scopusauthoridCrapez, E=6508367383en_HK
dc.identifier.scopusauthoridDuffour, J=6602444675en_HK
dc.identifier.scopusauthoridYchou, M=7005596512en_HK
dc.identifier.scopusauthoridLeahy, DT=36854766700en_HK
dc.identifier.scopusauthoridO'Donoghue, DP=7102494838en_HK
dc.identifier.scopusauthoridAgnese, V=9738565900en_HK
dc.identifier.scopusauthoridCascio, S=6701571149en_HK
dc.identifier.scopusauthoridDi Fede, G=7003846314en_HK
dc.identifier.scopusauthoridChiecoBianchi, L=7102292026en_HK
dc.identifier.scopusauthoridBertorelle, R=6701343591en_HK
dc.identifier.scopusauthoridBelluco, C=6701610645en_HK
dc.identifier.scopusauthoridGiaretti, W=7005374757en_HK
dc.identifier.scopusauthoridCastagnola, P=6701432645en_HK
dc.identifier.scopusauthoridRicevuto, E=6701828649en_HK
dc.identifier.scopusauthoridFicorella, C=7003957340en_HK
dc.identifier.scopusauthoridBosari, S=7003540682en_HK
dc.identifier.scopusauthoridArizzi, CD=6506565601en_HK
dc.identifier.scopusauthoridMiyaki, M=7005616139en_HK
dc.identifier.scopusauthoridOnda, M=36886363100en_HK
dc.identifier.scopusauthoridKampman, E=7003958833en_HK
dc.identifier.scopusauthoridDiergaarde, B=6602323610en_HK
dc.identifier.scopusauthoridRoyds, J=7003622251en_HK
dc.identifier.scopusauthoridLothe, RA=16171650300en_HK
dc.identifier.scopusauthoridDiep, CB=6602603171en_HK
dc.identifier.scopusauthoridMeling, GI=6701507759en_HK
dc.identifier.scopusauthoridOstrowski, J=7103303872en_HK
dc.identifier.scopusauthoridTrzeciak, L=6603170998en_HK
dc.identifier.scopusauthoridGuzińskaUstymowicz, K=6603490074en_HK
dc.identifier.scopusauthoridZalewski, B=6603620473en_HK
dc.identifier.scopusauthoridCapellá, GM=24368272500en_HK
dc.identifier.scopusauthoridMoreno, V=7103038363en_HK
dc.identifier.scopusauthoridPeinado, MA=7005828690en_HK
dc.identifier.scopusauthoridLönnroth, C=6603568519en_HK
dc.identifier.scopusauthoridLundholm, K=7006507691en_HK
dc.identifier.scopusauthoridSun, XF=7405617934en_HK
dc.identifier.scopusauthoridJansson, A=7103332100en_HK
dc.identifier.scopusauthoridBouzourene, H=7004673175en_HK
dc.identifier.scopusauthoridHsieh, LL=7101988952en_HK
dc.identifier.scopusauthoridTang, R=7202300284en_HK
dc.identifier.scopusauthoridSmith, DR=7410365759en_HK
dc.identifier.scopusauthoridAllenMersh, TG=7005359844en_HK
dc.identifier.scopusauthoridKhan, ZAJ=36944754900en_HK
dc.identifier.scopusauthoridShorthouse, AJ=7003658044en_HK
dc.identifier.scopusauthoridSilverman, ML=7403299034en_HK
dc.identifier.scopusauthoridKato, S=7404162320en_HK
dc.identifier.scopusauthoridIshioka, C=7005354286en_HK
dc.identifier.citeulike607473-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats